1Issa JP and KantarJian HP.Introduction emerging role of epigenetic therapy:Focus on Decitabine[J].Semin Hematal,2005,42 (3):1-2.
2Momparler RL.Pharmacology of 5-Aza-2 -deoxycytidine (decitabine)[J].Semin Hematol,2005,42(3):9-16.
3Saba HI,Wijermans PW.Decitabine in myelodysplastic syndroms[J].Semin Hematol,2005,42(3):23 -31.
4Issa J-PJ,Manero GG,Giles FJ,et al.Phase I study of tow-dose prolonged exposure schedule of the hypometylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies[J].Blood,2004,103(5):1636 -46.
5Kantarian HO,Brien S,Giles F,et al.Decitabine low-dose Schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS).Comparison of 3 different dose schedules[J].Blood,2005,106 (11):708.
6Saba HI,lbbert M,Wijermasns PW.Response rats of phase 2 and phase 3.Trials of decitabine (DAC) in patients with myelodys plastic syndromes(MDS)[J].Blood,2005,106(11):706.
7Lbbert M,Minden M.Decitabine in acute myeloid Leukemia[J].Semin Hematol,2005,42 (3):38-42.
8Lbbert M,Rueer B,Schmid M,et al.Contiuned tow-dose Decitabine (DAC) is an active first-line treatment of order AML patients:first results of a multicenter phase Ⅱstudy[J].Blood,2005,106(11):527.
9Cashen A,Shah A,Helget A,et al.A phase I phamacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)[J].Blood,2005,106(11):527.
10Scott SA,Dong WF,Ichinohasama R,et al.5-Aza-2'-deoxycytidine (decitabine) can relieve p21 WAF1 repression in human acute leukemia by a mechanism involving release of histone deacetylase 1 (HADC1) without requiring promoter demethylation[J].Leukemia Reseach,2006,30(1):69-76.
2WIJERMANS P,LUBBERT M,VERHOEF G,et al.Low-dose5-Aza-2'-deoxycytidine,a DNA hypomethylating agent,for the treatment of high-risk myelodysplastic syndrome:A multicenter phase Ⅱ study in elderly patients.Ann Hematol,2005,84(Suppl 13):9-17.
3WIJERMANS P W,LUBBERT M,VERHOEF G,et al.An epigenetic approach to the treatment of advanced MDS;the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine(decitabine) in 177 patients[J].Ann Hematol,2005,84(Suppl 13):9-17.
4陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:919.
5Ma X,Does M,Raza A,et al.Myelodysplastic syndromes:incidence and survival in the United States[J].Cancer,2007,109(8):1536-42.
6Cheson BD,Bennett J M,Kantarjian H,et al.Report of an international working group to standardize response criteria for myelodysplastic syndromes[J].Blood,2000,96(12):3671-4.
7Thomas ML.Strategies for achieving transfusion independence in myelodysplastic syndromes[J].Eur J Oncol Nurs,2007,11(2):151-8.
8Wijermans P, Lfibbert M, Verhoef G, et al. Low-dose 5-aza-2'-de- oxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin 0ncol,2000,18(5) :956-962.
9Wijermans PW, Liibbert M, Verhoef G, et al. An epigenetic ap- proach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol,2005,84 Suppl 1:9-17.
